Zurcher Kantonalbank Zurich Cantonalbank Sells 19,911 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 66.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,858 shares of the medical research company's stock after selling 19,911 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Charles River Laboratories International were worth $2,330,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in CRL. Everence Capital Management Inc. acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at $378,000. Flputnam Investment Management Co. increased its holdings in Charles River Laboratories International by 7.5% during the 4th quarter. Flputnam Investment Management Co. now owns 61,768 shares of the medical research company's stock worth $14,602,000 after purchasing an additional 4,293 shares during the period. Strs Ohio increased its holdings in shares of Charles River Laboratories International by 4.1% in the 4th quarter. Strs Ohio now owns 34,960 shares of the medical research company's stock valued at $8,264,000 after acquiring an additional 1,363 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $400,000. Finally, Louisiana State Employees Retirement System purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $733,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the company's stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company's stock, valued at $626,155.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Victoria L. Creamer sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now owns 13,550 shares in the company, valued at approximately $3,437,635. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock valued at $3,693,663 over the last three months. 1.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CRL. Argus raised their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a research note on Monday, March 18th. UBS Group raised their price target on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a "buy" rating in a research note on Thursday, February 15th. TheStreet upgraded Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Citigroup raised their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a research note on Thursday, February 15th. Finally, Evercore ISI raised their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an "outperform" rating in a research note on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $253.23.

Charles River Laboratories International Price Performance

CRL traded down $0.67 during trading on Wednesday, reaching $239.46. 705,117 shares of the stock were exchanged, compared to its average volume of 551,438. The business's 50 day moving average price is $254.15 and its two-hundred day moving average price is $222.36. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. The company has a market capitalization of $12.33 billion, a price-to-earnings ratio of 26.00, a P/E/G ratio of 1.82 and a beta of 1.40. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. During the same period in the previous year, the business earned $2.98 earnings per share. Charles River Laboratories International's quarterly revenue was down 7.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).